DrugPatentWatch Database Preview
Litigation Details for FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC (D.N.J. 2015)
» See Plans and Pricing
FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC (D.N.J. 2015)
| Docket | Start Trial | Date Filed | 2015-05-29 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Kevin McNulty |
| Jury Demand | Defendant | Referred To | Michael A. Hammer |
| Patents | 9,006,289; 9,168,238; 9,168,239 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC
The small molecule drug covered by the patents cited in this case is Start Trial .
Details for FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC (D.N.J. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-09-20 | 327 | harma”).’ The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent” … — “289 Patent” United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. …of the 4 (See, e.g., ‘289 Patent Claim 1; ‘238 Patent Claim 1; ‘239 Patent buffer. …’s construction of key patent terms following a Markman hearing. This patent infringement case is brough…PageID: 7183 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”). | External link to document | |
| 2016-09-20 | 328 | is for patent infringement. The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent”), 9,168,238…253- 4)). “‘289 Patent” — United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. 187—2)…limited patent monopoly. Where the patent holder is acting within the lawful scope of its patent, public…9,168,238 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”). All three describe formulations of levothyroxine…2). “238 Patent” — United States Patent No. 9,168,238, P1. Ex. 2 (ECF No. 187—3). | External link to document | |
| 2016-09-23 | 333 | is for patent infringement. The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent”), 9,168,238…253- 4)). “289 Patent” — United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. 187—2)…limited patent monopoly. Where the patent holder is acting within the lawful scope of its patent, public…9,168,238 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”). All three describe formulations of levothyroxine…2). “238 Patent” — United States Patent No. 9,168,238, P1. Ex. 2 (ECF No. 187—3). | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
